Cargando…

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients

Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK(+)) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cadranel, Jacques, Cortot, Alexis B., Lena, Hervé, Mennecier, Bertrand, Do, Pascal, Dansin, Eric, Mazieres, Julien, Chouaid, Christos, Perol, Maurice, Barlesi, Fabrice, Robinet, Gilles, Friard, Sylvie, Thiberville, Luc, Audigier-Valette, Clarisse, Vergnenegre, Alain, Westeel, Virginie, Slimane, Khemaies, Buturuga, Alexandru, Moro-Sibilot, Denis, Besse, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810621/ https://www.ncbi.nlm.nih.gov/pubmed/29450203 http://dx.doi.org/10.1183/23120541.00058-2017

Ejemplares similares

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
por: Girard, N., et al.
Publicado: (2020)

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
por: Molinier, O., et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Petrazzuolo, Adriana, et al.
Publicado: (2021)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
por: Barlesi, Fabrice, et al.
Publicado: (2020)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
por: Mansfield, A. S., et al.
Publicado: (2016)

Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
por: Zhu, Zhouyu, et al.
Publicado: (2017)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
por: Hoang, Tung, et al.
Publicado: (2020)

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
por: Kiura, Katsuyuki, et al.
Publicado: (2018)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
por: Liu, Maobai, et al.
Publicado: (2019)

Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
por: Guisier, F., et al.
Publicado: (2020)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
por: Huang, Shih‐Hao, et al.
Publicado: (2019)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
por: Cho, Byoung Chul, et al.
Publicado: (2023)

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report
por: Bing, Zhongxing, et al.
Publicado: (2021)

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
por: Gao, Peng, et al.
Publicado: (2022)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
por: Vergnenègre, A, et al.
Publicado: (2013)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
por: Remon, Jordi, et al.
Publicado: (2020)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2021)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report
por: Shen, Gang, et al.
Publicado: (2021)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
por: LeCaer, H, et al.
Publicado: (2011)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
por: Beck, Olaf, et al.
Publicado: (2020)

Préconisations pour protéger les patients de la filière oncologique face au variant Omicron
por: Barrière, Jérôme, et al.
Publicado: (2022)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

1629P Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network
por: Benitez, J.C., et al.
Publicado: (2022)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
por: Fujita, Haruka, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8djcrsvlkguos6knlmni4e412k